A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease (NCT06154837)
A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Yuma, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- GSK Investigational Site — Yuma, Arizona
- GSK Investigational Site — Hialeah, Florida
- GSK Investigational Site — Orange City, Florida
- GSK Investigational Site — Plantation, Florida
- GSK Investigational Site — Columbus, Georgia
- GSK Investigational Site — Shelby, North Carolina
- GSK Investigational Site — Medford, Oregon
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — Rock Hill, South Carolina
- GSK Investigational Site — Austin, Texas
- GSK Investigational Site — Ahrensburg,
- GSK Investigational Site — Berlin,
- GSK Investigational Site — Berlin,
- GSK Investigational Site — Berlin,
- GSK Investigational Site — Dresden,
- GSK Investigational Site — Frankfurt,
- GSK Investigational Site — Hamburg,
- GSK Investigational Site — Hamburg,
- GSK Investigational Site — Hanover,
- GSK Investigational Site — Immenhausen,
- GSK Investigational Site — Leipzig,
- GSK Investigational Site — Lübeck,
- GSK Investigational Site — Mainz,
- GSK Investigational Site — Schwerin,
- GSK Investigational Site — Barnsley,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Disease, Chronic Obstructive
- Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) — Birmingham, Alabama
- Evaluating the Clinical Effectiveness of a Patient-specific Silicone Stent — Rochester, Minnesota
- Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD — Minneapolis, Minnesota
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting — Mississauga,
- Innate Immunity in Ozone-induced Airway Inflammation in COPD — San Francisco, California
Explore by condition: All Pulmonary Disease, Chronic Obstructive clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.